MARKET

CHRS

CHRS

Coherus
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.61
-0.15
-0.80%
Opening 12:04 08/12 EDT
OPEN
18.82
PREV CLOSE
18.76
HIGH
19.11
LOW
18.45
VOLUME
336.72K
TURNOVER
--
52 WEEK HIGH
23.91
52 WEEK LOW
10.86
MARKET CAP
1.33B
P/E (TTM)
9.65
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CHRS stock price target is 30.44 with a high estimate of 35.00 and a low estimate of 22.00.

EPS

CHRS News

More
Coherus BioSciences (CHRS) Q2 Earnings and Revenues Top Estimates
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 169.23% and 35.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 5d ago
Coherus BioSciences Reports Second Quarter 2020 Financial Results
– Second Quarter UDENYCA® Net Sales of $135.7 Million – – Net Income of $59.0 Million – – Non-GAAP Net Income of $68.3 Million –REDWOOD CITY, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), toda
GlobeNewswire · 5d ago
Coherus BioSciences Appoints Kimberly Tzoumakas, J.D. to Board of Directors
REDWOOD CITY, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced the appointment of Kimberly Tzoumakas, J.D. to its Board of Directors effective July 30, 2020.  “We are very pleased to welcome Kimber
GlobeNewswire · 08/03 20:48
Earnings Preview: Coherus BioSciences (CHRS) Q2 Earnings Expected to Decline
Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/30 16:33
Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., July 17, 2020 -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective July 16, 2020, the compensation.
GlobeNewswire · 07/17 13:30
Coherus BioSciences to Report Second Quarter Financial Results on August 6th
REDWOOD CITY, Calif., July 16, 2020 -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its second quarter 2020 financial results will be released.
GlobeNewswire · 07/16 13:30
Did Hedge Funds Make The Right Call On Coherus Biosciences Inc (CHRS) ?
Insider Monkey · 07/10 01:56
Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., June 19, 2020 -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective June 18, 2020, the compensation.
GlobeNewswire · 06/19 13:30

Industry

Biotechnology & Medical Research
+0.08%
Pharmaceuticals & Medical Research
+1.42%

Hot Stocks

Symbol
Price
%Change

About CHRS

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.
More

Webull offers kinds of Coherus Biosciences Inc stock information, including NASDAQ:CHRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CHRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CHRS stock methods without spending real money on the virtual paper trading platform.